Younger Brain Age Buffers Cognitive Impact of Tau Pathology

The clinical management of Alzheimer disease remains a significant challenge as the global burden of neurodegenerative disorders continues to rise [1]. While the presence of amyloid and tau pathology is central to the disease, the degree of cognitive impairment often varies significantly between patients with similar pathological loads [2, 3]. This discrepancy has led to the hypothesis of cognitive reserve, suggesting that factors like education and mental activity may delay the onset of clinical symptoms [4, 5]. However, clinicians still lack standardized tools to quantify this resilience or predict which patients will maintain function despite emerging pathology [5]. A recent study investigates how specific structural and socioeconomic markers modify the relationship between tau levels and cognitive performance, offering insights into which patients might best tolerate early neurodegeneration.